In a small study in a community oncology practice, more than 60% of patients with advanced squamous cell skin cancer treated ...

The approval of Libtayo (cemiplimab) in advanced NSCLC is for first-line treatment of patients with 50% or more PD-L1 expression and no EGFR, ALK or ROS1 aberrations, taking the drug into a large ...

Regeneron stock jumped Tuesday after the biotech giant topped Wall Street's December-quarter calls on the back of its cancer drug Libtayo. The company also announced a dividend for the first time.

EMPOWER-Lung-3 enrolled subjects with both squamous and non-squamous tumours and all PD-L1 expression levels, so Libtayo's efficacy comes against a more heterogenous patient population.

The agreement was signed in a letter of intent March 3 to set the groundwork for whether government health programs in ...

THIO sequenced with Libtayo extended overall survival in those with non–small cell lung cancer who progressed on two or more standard-of-care regimens. Treatment with the lead clinical candidate THIO ...

Regeneron UK Limited has announced that the Scottish Medicines Consortium (SMC) has accepted Libtayo (cemiplimab ... Treatment options are also more limited in advanced stages. In Scotland, only 20% ...

A ~$4.5B share repurchase program adds further value. LIBTAYO demonstrated massive growth, accelerating to 50% in Q4 2024 versus Q4 2023. Approval in CSCC means that this growth catalyst is ...

Regeneron UK Limited today announced that the Scottish Medicines Consortium (SMC) has accepted Libtayo ® (cemiplimab ... Treatment options are also more limited in advanced stages.

The supply agreement supports the evaluation of Immuneerings' lead product candidate, IMM-1-104, in combination with Regeneron's immunotherapy drug Libtayo in patients with advanced non-small cell ...